CHARM Therapeutics’ Post

🚀 Revolutionizing Drug Discovery with AI 💊 The world of drug discovery is witnessing an unprecedented transformation, thanks to artificial intelligence (AI)! 🤖 By sifting through and analyzing massive volumes of data, AI is unlocking valuable insights that can pave the way for groundbreaking medical treatments. 🧪 Among the most promising AI tools are deep-learning models like generative adversarial networks (GANs) and Autoencoders. These cutting-edge technologies are not only expediting the creation of new drugs but also enhancing their quality and effectiveness. 📈 As the benefits of AI become increasingly apparent, we're seeing a surge in collaborations between AI and pharmaceutical companies. Together, they're committed to developing drug candidates in a swift, efficient, and cost-effective manner, ultimately revolutionizing the way we approach healthcare. 🌟 Source in comment Take a look at our discussion with Dr. Violet Zahedi, cofounder at Synamics Therapeutics working on this game-changing intersection of AI and medicine! 💡 👉https://lnkd.in/eHg5AH4M #AIinHealthcare #DrugDiscovery #Innovation #MedTech #cancer #oncology #drugdesign

Hype vs. Reality: The #AI Revolution in #drugdiscovery - I think we are still in the very early days.. UK-based Exscientia and its AI-designed cancer drug, EXS-21546, alongside similar endeavors by BenevolentAI and Recursion, faced clinical hurdles. the market didn't respond well; stocks have plummeted, reflecting investor skepticism. We have to remind ourselves that R&D success in #pharma is very limited and these are only handful of early experiments. Companies like Generate:Biomedicines, Verge Genomics, BPGbio Inc., Insilico Medicine, Auransa and Nimbus Therapeutics continue to push the envelope in integrating #AI. We need to remind ourselves about Moderna's covid success. This is a journey demanding patience, perseverance, and a nuanced understanding of both technology's capabilities and limitations.

🚀 Dive into the future of drug discovery! Join us this Wednesday, February 28, for a live discussion on #Xspaces. 🤖🧬 @Rakovina_RKV in collaboration with Follow the Money Investor Group Discover the transformative power of AI in the drug discovery process with insights from industry leaders 👇 Jeffrey Bacha, our Executive Chairman Mads Daugaard, our President & Chief Scientific Officer and Artem Cherkasov, the newest member of our Scientific Advisory Board Don't miss out on this dynamic conversation shaping the future of oncology. See you there! 👩🔬👨💼 #AI #DrugDiscovery #Innovation #biotech

🚀 Dive into the future of drug discovery! Join us this Wednesday, February 28, for a live discussion on #Xspaces. 🤖🧬 @Rakovina_RKV in collaboration with Follow the Money Investor Group Discover the transformative power of AI in the drug discovery process with insights from industry leaders 👇 Jeffrey Bacha, our Executive Chairman Mads Daugaard, our President & Chief Scientific Officer and Artem Cherkasov, the newest member of our Scientific Advisory Board Don't miss out on this dynamic conversation shaping the future of oncology. See you there! 👩🔬👨💼 #AI #DrugDiscovery #Innovation #biotech

Check out this new eBook from Drug Discovery World, “Using Imaging in Drug Discovery,” where you can learn more about: • How new imaging modalities are supporting the development of new therapies for cancer and neurodegenerative diseases. • The benefits of integrating #AI with medical imaging for clinical trials via Flywheel and the NVIDIA MONAI toolkit. • And more We were excited to be a part of this piece exploring the important role that analysis-ready imaging plays in drug discovery. Download now to learn more.

Our CEO and co-founder, Avi Veidman, was featured in a STAT article, emphasizing the importance of spatial AI biomarkers in improving patient enrollment for clinical trials. The piece explores how AI is revolutionizing drug development and propelling precision medicine forward. Dive into the full story for more insights. 📖✨ https://bit.ly/4aIKOPL #spatialbiomarkers #AI #biopharma #clinicaltrials #CDx #biomarkers #precisionmedicine #precisiononcology #spatialbiology

💡 Ever wondered what it means to have a strategic investor at the table? We're thrilled to share this article from Sifted featuring our Innovation Fund's strategic investments in Genialis and Nucleai! Learn about our collaborations with these two startups, leading the charge in using artificial intelligence to discover predictive biomarkers and map complex cellular interactions. These efforts are paving the way towards improved clinical trial success rates. These initiatives highlight the pivotal role of our Innovation Fund in advancing AI technologies in healthcare, particularly in oncology. By bridging startups like Genialis and Nucleai with the pharmaceutical industry, the Fund accelerates innovation with agile approaches to tackle complex medical challenges. This collaborative approach not only has the potential to speed up drug development, but also catalyzes transformative advancements in precision medicine, delivering more effective solutions for patients. We eagerly anticipate reaching new milestones as these AI-driven solutions reshape the landscape of healthcare. Featuring: Carolina Haefliger, Anna Pokorska-Bocci, Marc Cikes, Rafael Rosengarten (Genialis) and Avi Veidman (Nucleai). #AI #HealthcareInnovation #CancerResearch #PrecisionMedicine #ClinicalTrial

A deep dive discussion from Labiotech.eu into Insilico's collaboration with University of Toronto and Igor Stagljar to design novel molecules for 15-20 "undruggable" cancer targets and the advances in Insilico's generative AI drug discovery platform, Pharma.AI, with Kyle Tretina, PhD, alliance manager of AI platforms. ➡ On the topic of "undruggability," he says: “There’s a lot of different things that can make a target undruggable, and AI can really help with quite a few of them. So first would be structural unavailability. When a protein is acting in a signaling pathway that is related to the development of a disease, there’s usually certain parts of the protein that are involved in that process more than other parts. “If it’s an enzyme, there’s maybe a little pocket that is involved in changing other molecules and enabling signaling. So it might be actually the case that the drug target may be structurally unsuitable for drug binding within that pocket where you want the small molecule to bind for chemical reasons. This is really where I think AI has been extremely powerful because of that imaginative ability." *Link to podcast and article in comments #ai #platform #drugdiscovery #undruggable #cancer #targetid #chemistry #pharma

🚨 Breaking news 🚨 iktos acquires SYNSIGHT, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery. As Yann Gaston-Mathe, CEO and Co-founder of Iktos comments « The acquisition of Synsight enables Iktos to expand its platform to new modulators of Protein-Protein interaction’s and RNA-Protein Interaction’s, historically highly challenging targets, thereby addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases » The merger further complements Iktos' AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testing thanks to MT Bench technology originally developed at INSERM. 👉 To learn more about this acquisition: https://lnkd.in/ez7hHmM8 #drugdiscovery #artificialintelligence #proteinproteininteractions #RNAinteractions Genopole Medicen Paris Region

T-1 day until DDIF 2024 GBX EVENTS kicks off! Excited to dive into groundbreaking presentations from industry leaders on innovations in digital transformation, GenAI, AI-driven drug discovery, and more. Key topics: - GenAI's role in healthcare and pharma - Transforming cancer and age-related treatments with AI and cell therapy - Patient-first drug discovery - The impact of quantum computing Looking forward to the fireside chats and hearing insights from CxOs about their journey and vision for the future. Exciting times for healthcare ahead!